Payment overview · 2025
General Payments
$36,050.67
70 reported records · 21 companies
Healthcare provider profile · identity verified
Luis J Navazo, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · OCEANSIDE, CA · NPI 1043359219
Verified facts
What the public records show
CMS Open Payments records show Luis J Navazo, M.D. received $36,050.67 in general payments during 2025 across 70 reported records.
Neurocrine BioSciences, Inc. accounted for 63.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ingrezza, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22,725.97 | 63.0% | 25 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $9,930.79 | 27.6% | 12 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $1,667.46 | 4.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $647.92 | 1.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $167.70 | 0.5% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $128.35 | 0.4% | 4 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $120.20 | 0.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.00 | 0.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $118.31 | 0.3% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $78.27 | 0.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $70.07 | 0.2% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $40.92 | 0.1% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $40.06 | 0.1% | 2 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $35.00 | 0.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.67 | 0.1% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $27.72 | 0.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $25.23 | 0.1% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $21.02 | 0.1% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $20.01 | 0.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.72 | 0.1% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.28 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,043.00 | 9 |
| Consulting Fee | $9,897.50 | 3 |
| Food and Beverage | $2,959.16 | 50 |
| Travel and Lodging | $1,151.01 | 7 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,000.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $17,621.05 | 22 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $9,930.79 | 12 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $1,667.46 | 3 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $1,667.46 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $647.92 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $237.77 | 6 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $128.35 | 4 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $120.20 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $120.00 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $118.31 | 1 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ Normalized: aquacel ag |
Device | ConvaTec Inc. | $78.27 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $40.92 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $40.06 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $39.86 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $29.67 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $21.02 | 1 | 2025 |
Source payment records
|
|||||
| PURAPLY WOUND MATRIX Normalized: puraply wound matrix |
Device | Organogenesis Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
209 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
132 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 478 | 69 |
| Eliquis | Apixaban | 407 | 53 |
| Xarelto | Rivaroxaban | 384 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 373 | 71 |
| Gabapentin | Gabapentin | 342 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 278 | 35 |
| Divalproex Sodium | Divalproex Sodium | 272 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 48 |
| Furosemide | Furosemide | 247 | 43 |
| Vascepa | Icosapent Ethyl | 238 | 32 |
| Potassium Chloride | Potassium Chloride | 237 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 41 |
| Losartan Potassium | Losartan Potassium | 221 | 42 |
| Farxiga | Dapagliflozin Propanediol | 209 | 31 |
| Mirtazapine | Mirtazapine | 206 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 204 | 39 |
| Trazodone Hcl | Trazodone Hcl | 176 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 175 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 169 | 29 |
| Metformin Hcl | Metformin Hcl | 165 | 22 |
| Famotidine | Famotidine | 164 | 25 |
| Finasteride | Finasteride | 158 | 24 |
| Lisinopril | Lisinopril | 149 | 29 |
| Mounjaro | Tirzepatide | 132 | 19 |
| Donepezil Hcl | Donepezil Hcl | 130 | 18 |
| Sertraline Hcl | Sertraline Hcl | 123 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 115 | 24 |
| Simvastatin | Simvastatin | 104 | 11 |
| Dapagliflozin | Dapagliflozin Propanediol | 101 | 19 |
| Memantine Hcl | Memantine Hcl | 99 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 20 |
| Levetiracetam | Levetiracetam | 94 | 15 |
| Carvedilol | Carvedilol | 92 | 23 |
| Omeprazole | Omeprazole | 90 | 22 |
| Nystatin | Nystatin | 89 | 36 |
| Amiodarone Hcl | Amiodarone Hcl | 88 | 15 |
| Celecoxib | Celecoxib | 88 | 11 |
| Allopurinol | Allopurinol | 83 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 20 |
| Latanoprost | Latanoprost | 76 | 16 |
| Montelukast Sodium | Montelukast Sodium | 75 | 14 |
| Pregabalin | Pregabalin | 73 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 15 |
| Myrbetriq | Mirabegron | 69 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 65 | suppressed |
| Entresto | Sacubitril/Valsartan | 64 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 61 | 16 |
| Olanzapine | Olanzapine | 60 | suppressed |
| Risperidone | Risperidone | 59 | suppressed |
| Ezetimibe | Ezetimibe | 57 | suppressed |
| Haloperidol | Haloperidol | 57 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 56 | 15 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 54 | suppressed |
| Rivastigmine | Rivastigmine | 52 | suppressed |
| Baclofen | Baclofen | 51 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 12 |
| Aripiprazole | Aripiprazole | 48 | suppressed |
| Atenolol | Atenolol | 48 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 46 | suppressed |
| Spironolactone | Spironolactone | 44 | 13 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Lactulose | Lactulose | 39 | 15 |
| Naproxen | Naproxen | 39 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | suppressed |
| Xifaxan | Rifaximin | 38 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Midodrine Hcl | Midodrine Hcl | 37 | suppressed |
| Timolol Maleate | Timolol Maleate | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 11 |
| Methylprednisolone | Methylprednisolone | 34 | 27 |
| Hydrocortisone | Hydrocortisone | 33 | suppressed |
| Ingrezza | Valbenazine Tosylate | 33 | suppressed |
| Ozempic | Semaglutide | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Bumetanide | Bumetanide | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 28 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Lorazepam | Lorazepam | 27 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 18 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Carbamazepine | Carbamazepine | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Rexulti | Brexpiprazole | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 18 |
| Imiquimod | Imiquimod | 23 | 11 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Divalproex Sodium Er | Divalproex Sodium | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Levemir | Insulin Detemir | 20 | suppressed |
| Linzess | Linaclotide | 20 | 12 |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Jardiance | Empagliflozin | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Austedo | Deutetrabenazine | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Cilostazol | Cilostazol | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Trimethoprim | Trimethoprim | 15 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Dayvigo | Lemborexant | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Gralise | Gabapentin | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $36,050.67 · 70 records | Neurocrine BioSciences, Inc. | AIRSUPRA, AQUACEL AG+, AREXVY, AUSTEDO XR, BRIXADI, COLLAGENASE SANTYL, FANAPT, HETLIOZ, INGREZZA, KISUNLA, Kerecis GraftGuide, Kerecis SurgiClose, Kerendia, NUPLAZID, PURAPLY WOUND MATRIX, REXULTI, SHINGRIX, SUBLOCADE, UBRELVY, WATCHMAN, YUPELRI | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ingrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error